We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+33%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$19.5B
AUM Growth
+$4.67B
(+31%)
Cap. Flow
+$750M
Cap. Flow
% of AUM
3.84%
Top 10 Holdings %
Top 10 Hldgs %
35.61%
Holding
917
New
102
Increased
528
Reduced
232
Closed
53
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Newmont
NEM
|
+$271M |
| 2 |
B
Barrick Mining
B
|
+$177M |
| 3 |
GG
Goldcorp Inc
GG
|
+$137M |
| 4 |
SSRI
Silver Standard Resources
SSRI
|
+$107M |
| 5 |
Franco-Nevada
FNV
|
+$105M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Valero Energy
VLO
|
+$134M |
| 2 |
Pan American Silver
PAAS
|
+$129M |
| 3 |
BHI
Baker Hughes
BHI
|
+$85.7M |
| 4 |
Kinder Morgan
KMI
|
+$77.5M |
| 5 |
SEMG
SEMGROUP CORPORATION
SEMG
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 57.74% |
| 2 | Energy | 17% |
| 3 | Healthcare | 5.04% |
| 4 | Industrials | 2.41% |
| 5 | Technology | 2.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Merck
MRK
$322B
| $13.2M | 0.07% |
240,191
-19,155
| -7% | -$1.02M |
|
177
Pfizer
PFE
$143B
| $13.2M | 0.07% |
394,866
-64,351
| -14% | -$2.05M |
|
|
SDRL
178
DELISTED
Seadrill Limited Common Stock
SDRL
| $13.1M | 0.07% |
15,085
-7
| -0% | -$6.66K |
|
179
FMC
FMC
$1.46B
| $12.9M | 0.07% |
321,406
+1,942
| +0.6% | +$76.1K |
|
180
Toro Company
TTC
$8.72B
| $12.7M | 0.07% |
287,650
+21,458
| +8% | +$937K |
|
|
FTRPR
181
DELISTED
Frontier Communications Corporation 11.125% Series A Mandatory Convertible Preferred Stock
FTRPR
| $12.6M | 0.06% |
133,212
+35,869
| +37% | +$3.55M |
|
|
NVO
182
Novo Nordisk
NVO
$213B
| $12.4M | 0.06% |
461,908
-3,850
| -0.8% | -$106K |
|
183
Perrigo
PRGO
$1.4B
| $12.2M | 0.06% |
134,769
+18,044
| +15% | +$1.87M |
|
184
AstraZeneca
AZN
$261B
| $12.1M | 0.06% |
200,494
+1,353
| +0.7% | +$78.6K |
|
185
Abbott
ABT
$175B
| $12M | 0.06% |
305,455
+8,569
| +3% | +$341K |
|
186
Charles River Laboratories
CRL
$11B
| $11.8M | 0.06% |
143,582
+16,186
| +13% | +$1.33M |
|
|
MDR
187
DELISTED
McDermott International
MDR
| $11.6M | 0.06% |
785,903
+51,333
| +7% | +$693K |
|
|
SHPG
188
DELISTED
Shire pic
SHPG
| $11.6M | 0.06% |
63,012
-10,295
| -14% | -$1.86M |
|
189
Vale
VALE
$63.1B
| $11.6M | 0.06% |
2,291,058
+760,668
| +50% | +$3.56M |
|
190
Huazhu Hotels Group
HTHT
$12.5B
| $11.3M | 0.06% |
+1,240,000
| New | +$10.9M |
|
191
Teva Pharmaceuticals
TEVA
$36.3B
| $11.2M | 0.06% |
223,792
+19,078
| +9% | +$1.02M |
|
192
Viatris
VTRS
$20.1B
| $11.2M | 0.06% |
259,352
+63,229
| +32% | +$2.8M |
|
|
XLNX
193
DELISTED
Xilinx Inc
XLNX
| $10.9M | 0.06% |
236,458
+119,109
| +101% | +$5.44M |
|
194
Home Depot
HD
$324B
| $10.9M | 0.06% |
85,055
-16,242
| -16% | -$2.15M |
|
195
Skyworks Solutions
SWKS
$9.1B
| $10.8M | 0.06% |
171,018
+66,037
| +63% | +$4.49M |
|
|
KMI.PRA
196
DELISTED
Kinder Morgan, Inc.
KMI.PRA
| $10.8M | 0.06% |
221,443
+59,627
| +37% | +$2.72M |
|
197
United Therapeutics
UTHR
$26.4B
| $10.7M | 0.05% |
101,102
-14,253
| -12% | -$1.59M |
|
|
AMT.PRB
198
DELISTED
American Tower Corporation
AMT.PRB
| $10.7M | 0.05% |
+95,151
| New | +$10M |
|
|
RIC
199
DELISTED
Richmont Mines Inc.
RIC
| $10.3M | 0.05% |
1,115,500
+495,500
| +80% | +$3.86M |
|
|
TMUSP
200
DELISTED
T-Mobile US, Inc.5.50% Mandatory Convertible Preferred Stock, Series A
TMUSP
| $10.2M | 0.05% |
138,402
+37,267
| +37% | +$2.62M |
|
Similar funds
DAM
VanEck Associates's Q2 2016 Portfolio in Review
As of Q2 2016, VanEck Associates held 917 positions worth $19.5B, up 31% from $14.8B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
VanEck Associates deployed $750M of net new capital in Q2 2016, opening 102 new positions and adding to 528 existing holdings. Its largest new stake was Innovex International: 334,392 shares worth $19.5M.
By sector, the portfolio is most concentrated in Materials at 58% of assets, up from 48% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was Valero Energy, an estimated $134M trimmed.
- VanEck Associates's largest Q2 2016 buy was Innovex International: 334,392 shares worth $19.5M.
- VanEck Associates added most to Newmont in Q2 2016, an estimated $271M increase.
- VanEck Associates's biggest Q2 2016 reduction was Valero Energy, cutting an estimated $134M.
- VanEck Associates fully exited CAMERON INTERNATIONAL CORPORATION in Q2 2016, selling an estimated $45.1M.
- VanEck Associates's ten largest holdings make up 36% of its $19.5B portfolio in Q2 2016.
- VanEck Associates opened 102 new positions and closed 53 in Q2 2016.
- VanEck Associates's portfolio value rose 31% quarter-over-quarter to $19.5B.
Based on VanEck Associates's 13F filing for Q2 2016, filed 12 Aug 2016.